immuno-oncology

Two Ways to Take Charge of CAR T-Cell Therapy CostsSuccessful CAR T-cell therapy reimbursement begins with careful payer-provider collaboration and taking these two approaches.
Immuno-oncology bladder drug wins approvalSoon after approving the same drug for metastatic Merkel cell carcinoma, FDA approved immuno-oncology avelumab (Bavencio) for locally advanced or metastatic urothelial carcinoma.